• 목록
• 답변

iCURE announced on May 3 that it has signed an exclusive supply agreement with U.S. pharmaceutical company Arbomed Pharmacuticals Inc. U.S. for
the Treatment for Parkinson's Disease: Rotigotin Drug Patch.

Earlier, the company has signed iCure’s pain relief patch distribution agreement with Arbormed in January 2018. In addition, it signed an exclusive sales agreement for Rotigotin.
The contract period is until July 2032.

Rotigotin patches are drugs prescribed for the treatment of Parkinson's and lower extremity anxiety syndrome. It is characterized by improving the
the function of dopamine receptors in patients with Parkinson's disease who lack dopamine and improving motor disorders such as muscle tremors and stiffness.

In addition, iCURE has recently ended its third phase of global clinical trials of Donne Pezil Dementia Patch, a treatment for Alzheimer's dementia,
and is set to announce its clinical presentation in November.  In October, the U.S. is planning to apply for phase 1 clinical trial IND for the Donepezil dementia patch.

After the approval of the U.S. item license, iCURE is discussing strategies to expand the local market by completing the plant in Wanju based on the cGMP-level design
 and recently signing a cGMP consulting contract with Estima, a consulting firm specializing in cGMP and EUGMP.

Meanwhile, Arbormed Pharmaceutics in Silicon Valley is a U.S. pharmaceutical company that conducts clinical trials, FDA approval, drug price registration,
 and distribution of specialized drugs introduced by external research institutes or companies.